INNA-051 is under clinical development by ENA Respiratory and currently in Phase II for Influenza A Virus, H1N1 Subtype Infections. According to GlobalData, Phase II drugs for Influenza A Virus, H1N1 Subtype Infections have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INNA-051’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INNA-051 (INNA-X) is under development for the treatment of rhinovirus infections, influenza A virus, H1N1 subtype infections, seasonal influenza, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and lung diseases. It is a synthetic, pegylated targeting toll like receptor 2/toll like receptor 6 (TLR2/6) agonist and is administered by nasal route.
ENA Respiratory overview
ENA Respiratory is developing INNA-051, a broad-spectrum antiviral innate immunomodulator for pre and post-exposure prophylaxis of respiratory viral infections including COPD and asthma. The company is a spin-off of Axelia Oncology Pty Ltd. ENA Respiratory is headquartered in Melbourne, Victoria, Australia.
For a complete picture of INNA-051’s drug-specific PTSR and LoA scores, buy the report here.